PPII Coenzyme A Inc (CE)

Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary Coenzyme-A Technologies, Inc., is pleased to announce its latest innovative proprietary formulation, the COENZYME A MODULATOR MATRIX II™. The formula contains a balanced combination of active nutritional components that support the body's natural management of fat. This "BODY IMAGE™ product, in conjunction with proper diet and exercise, can produce phenomenal results in fat loss, while maintaining energy levels and preventing hunger and weakness," stated Nickolaos D. Skouras, PhD, President/CEO Coenzyme-A Technologies, Inc. "We are confident this is the first nutraceutical product to combine nutritional components that can be used by the body to support its manufacture and utilization of Acetyl Coenzyme-A with a specific set of substrates that are designed to assist the body in stabilizing blood sugar levels and metabolizing fat," Dr. Skouras added.

The world nutraceutical market, which is expected to top $15 billion this year, has enjoyed double-digit growth over the last few years and is expected to continue. Growth is believed to be driven by new product introductions and health consciousness within the aging populations. The US baby boomers, which are expected to reach 80 million by 2012, drive the US market in the sense that they are the generation which is most likely to demand control over the course of their medical care. Coenzyme-A Technologies, Inc. plans to penetrate this market through new and existing distribution channels as well as the implementation of an aggressive world-wide Internet marketing campaign.

ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the deleterious effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.

FORWARD LOOKING STATEMENTS

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Add to Digg Bookmark with del.icio.us Add to Newsvine

INVESTOR RELATIONS at: InvestSource, Inc. 6352 Santa Ynez Dr. Huntington Beach, CA 92647 Phone (714) 847-2460 Fax (714) 847-4987